🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › Texas › Houston

Diffuse Large B-Cell Lymphoma clinical trials in Houston, TX

17 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

RecruitingPhase 1/2
  • Md Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

RecruitingPhase 1
  • Baylor College of Medicine, Houston
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07226843

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
  • University of Texas MD Anderson Cancer Center ( Site 1007), Houston
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

RecruitingPhase 1
  • Md Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

RecruitingPhase 2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07284433

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RecruitingPhase 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

RecruitingPhase 3
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

RecruitingPhase 1
  • The University of TX MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833

DALY II USA/ MB-CART2019.1 for DLBCL

RecruitingPhase 2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

RecruitingObservational study
  • Texas Children's Hospital, Houston
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

RecruitingPhase 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Ages 18 and older · All sexes · Updated Oct 20, 2025 · NCT05890352

A Study of NX-1607 in Adults With Advanced Malignancies

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674

Diffuse Large B-Cell Lymphoma trials in other cities

Other studies in Houston

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.